JPMorgan: Maintains "Overweight" rating on Insilico Medicine (03696.HK), target price HK$71

Zhitong Finance APP has learned that JPMorgan issued a research report stating that Insilico Medicine's (03696.HK) recent progress in longevity research has strengthened its differentiated advantages in the AI drug discovery (AIDD) industry; the bank maintains an "Overweight" rating on Insilico Medicine, with a target price of HK$71, based on a sum-of-the-parts (SOTP) valuation as of December 2027, in which drug discovery and software solutions and other businesses adopt EV/S multiples of 17.5x and 8.9x respectively, implying a 2027 forecast price-to-sales ratio of about 19x, at the lower end of the global AIDD peer range of 5x to 173x (median about 60x).